Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.

NCT06164275 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06164275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06164275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 6, 2024
Completion date
December 31, 2031
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

classic hodgkin lymphoma